Leerink Partnrs Has Negative Forecast for Amgen Q4 Earnings

Amgen Inc. (NASDAQ:AMGN) – Research analysts at Leerink Partnrs cut their Q4 2025 earnings per share estimates for shares of Amgen in a research note issued on Tuesday, November 4th. Leerink Partnrs analyst D. Risinger now expects that the medical research company will post earnings per share of $4.64 for the quarter, down from their prior estimate of $5.00. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. Leerink Partnrs also issued estimates for Amgen’s FY2027 earnings at $20.06 EPS and FY2029 earnings at $18.57 EPS.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter last year, the company posted $5.58 earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.

AMGN has been the subject of a number of other research reports. Citigroup boosted their target price on shares of Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 24th. Raymond James Financial initiated coverage on Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating on the stock. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research report on Saturday. Cantor Fitzgerald raised their target price on Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Wednesday. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $308.83.

Amgen Price Performance

NASDAQ AMGN opened at $320.20 on Friday. Amgen has a 1 year low of $253.30 and a 1 year high of $335.88. The company has a fifty day simple moving average of $289.94 and a 200 day simple moving average of $288.50. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The company has a market cap of $172.38 billion, a P/E ratio of 26.18, a P/E/G ratio of 2.61 and a beta of 0.45.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, November 21st. Amgen’s payout ratio is currently 73.57%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.76% of the stock is currently owned by company insiders.

Institutional Trading of Amgen

A number of institutional investors and hedge funds have recently modified their holdings of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Amgen by 22.5% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 192,706 shares of the medical research company’s stock valued at $53,918,000 after purchasing an additional 35,423 shares in the last quarter. Wealth Alliance LLC boosted its stake in Amgen by 4.6% during the third quarter. Wealth Alliance LLC now owns 13,412 shares of the medical research company’s stock worth $3,785,000 after buying an additional 595 shares in the last quarter. King Luther Capital Management Corp increased its holdings in Amgen by 0.3% in the 3rd quarter. King Luther Capital Management Corp now owns 509,158 shares of the medical research company’s stock valued at $143,684,000 after buying an additional 1,653 shares during the period. Piedmont Capital Management LLC raised its stake in shares of Amgen by 2.5% in the 3rd quarter. Piedmont Capital Management LLC now owns 2,687 shares of the medical research company’s stock valued at $801,000 after buying an additional 65 shares in the last quarter. Finally, MRP Capital Investments LLC acquired a new position in shares of Amgen in the 3rd quarter valued at $181,000. 76.50% of the stock is currently owned by institutional investors.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.